Publications on the Chemotherapy-Resistance Test (CTR-Test®)

In the following, you will find a selection of the most significant publications on clinical studies and on the application of the Chemotherapy-Resistance Test – also called Extreme-Drug-Resistance Assay – to the analysis of patient specimens (validation studies).

Clinical Studies

The following studies verify the predictive power of the test and the benefit for the patient.


Gynecol Oncol. 2002 Oct;87(1):8-16.

5. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML


8. Extreme drug resistance is common after prior exposure to paclitaxel. Geisler JP, Linnemeier GC, Thomas AJ, Manahan KJ
Gynecologic Oncology. 2007;106:538-540.


10. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian, and peritoneal cancer. Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB

11. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinoma. Matsuo K, Eno ML, Im DD, Rosenshein NB

Publications on CTR-Test®


J Gynecol Oncol. 2009 June;20(2):96-100.


16. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer. Pant AC, Diaz-Montes T, Tanner E, Ahmad S, Giuntoli RL, Holloway RW, Bristow RE.

17. Extreme drug resistance for carboplatin predicts resistance to first line therapy in advanced stage ovarian cancer: results from the EORTC-GCG/NCIC-CTG neoadjuvant trial. Verleye L, Coens C, Arnant F, van der Burg MEL, Johnson N, Verheijen R, Casado A, Reed NS, Parker RJ, Vergote I
Communication at the 12th Biennial meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand, October 25-28, 2008 (abs.).

Validation Studies

The test was validated on patient specimens during the following studies.


Gynecol Oncol. 2005 Sep;98(3):360-8.


7. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. McAlpine JN, Eisenkop SM, Spirtos NM.
Gynecol Oncol. 2008 Sep;110(3):360-4.
